These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6094785)

  • 1. Pharmacokinetics and bioavailability of ranitidine in humans.
    Miller R
    J Pharm Sci; 1984 Oct; 73(10):1376-9. PubMed ID: 6094785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
    Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ranitidine following oral administration with ascending doses and with multiple-fixed doses.
    Garg DC; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1985 Sep; 25(6):437-43. PubMed ID: 4056078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioavailability of cimetidine in humans.
    Pedersen PV; Miller R
    J Pharm Sci; 1980 Apr; 69(4):394-8. PubMed ID: 7373532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranitidine disposition and systemic availability in hepatic cirrhosis.
    Smith IL; Ziemniak JA; Bernhard H; Eshelman FN; Martin LE; Schentag JJ
    Clin Pharmacol Ther; 1984 Apr; 35(4):487-94. PubMed ID: 6323087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications and simulations of a discontinuous oral absorption pharmacokinetic model.
    Witcher JW; Boudinot FD
    Pharm Res; 1996 Nov; 13(11):1720-4. PubMed ID: 8956341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ranitidine on the disposition of orally and intravenously administered triazolam.
    Vanderveen RP; Jirak JL; Peters GR; Cox SR; Bombardt PA
    Clin Pharm; 1991 Jul; 10(7):539-43. PubMed ID: 1860302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
    Morichau-Beauchant M; Houin G; Mavier P; Alexandre C; Dhumeaux D
    Dig Dis Sci; 1986 Feb; 31(2):113-8. PubMed ID: 3943439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two compartmental models for describing ranitidine's plasmatic profiles.
    Schaiquevich P; Niselman A; Rubio M
    Pharmacol Res; 2002 May; 45(5):399-405. PubMed ID: 12123628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of antacid and propantheline on the absorption of oral ranitidine.
    Donn KH; Eshelman FN; Plachetka JR; Fabre L; Powell JR
    Pharmacotherapy; 1984; 4(2):89-92. PubMed ID: 6326064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
    Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ratio of first to zeroth moments of the plasma profile of an oral drug undergoing first-pass and linear reversible metabolism.
    Cheng H
    Biopharm Drug Dispos; 1995 Dec; 16(9):791-6. PubMed ID: 8580402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption.
    Plusquellec Y; Efthymiopoulos C; Duthil P; Houin G
    Med Eng Phys; 1999 Oct; 21(8):525-32. PubMed ID: 10672785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers.
    Rao BN; Srinivas M; Kumar YS; Rao YM
    Drug Metabol Drug Interact; 2007; 22(2-3):175-85. PubMed ID: 17708067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of ranitidine.
    Roberts CJ
    Clin Pharmacokinet; 1984; 9(3):211-21. PubMed ID: 6329583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of estulic [corrected] in humans.
    Cherruault Y; Sarin VB
    Int J Biomed Comput; 1986 Mar; 18(2):123-30. PubMed ID: 3516889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism.
    Brown AS; Fiaterone JR; Day CP; Bennett MK; Kelly PJ; James OF
    Gut; 1995 Sep; 37(3):413-7. PubMed ID: 7590440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.
    Yin OQ; Tomlinson B; Chow AH; Chow MS
    Clin Pharmacokinet; 2003; 42(2):179-92. PubMed ID: 12537516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects.
    Shim CK; Hong JS
    J Pharm Sci; 1989 Dec; 78(12):990-4. PubMed ID: 2614701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
    Kakuda TN; Falcon RW
    Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.